Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Murali

Showing results (121-130 of 144) with videos related to

Pageof 15
Sort By:
Journal of Medicinal Chemistry|December 2, 1999
Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 2. Approaches to eliminate opioid agonist metabolites via modification of linker and 4-methoxycarbonyl-4-phenylpiperidine moietyT G Murali Dhar, D Nagarathnam, M R Marzabadi, et al.
Journal of Medicinal Chemistry|January 25, 2021
Bicyclic Ligand-Biased Agonists of S1P<sub>1</sub>: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety ProfilesJohn L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Bioorganic & Medicinal Chemistry Letters|July 2, 2019
Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonistsZhonghui Lu, James J-W Duan, Haiyun Xiao, et al.
Bioorganic & Medicinal Chemistry Letters|May 28, 2013
The discovery of BMS-457, a potent and selective CCR1 antagonistDaniel S Gardner, Joseph B Santella, John V Duncia, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse AgonistsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry|September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase InhibitorChunjian Liu, James Lin, John Hynes, et al.
Journal of Medicinal Chemistry|February 16, 2021
Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313Michael G Yang, Myra Beaudoin-Bertrand, Zili Xiao, et al.
Journal of the American Chemical Society|September 15, 2022
Overcoming Limitations in Decarboxylative Arylation via Ag-Ni ElectrocatalysisMaximilian D Palkowitz, Gabriele Laudadio, Simon Kolb, et al.
Journal of Medicinal Chemistry|May 17, 2002
Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activityT G Murali Dhar, Zhongqi Shen, Junqing Guo, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2020
Tricyclic sulfones as potent, selective and efficacious RORγt inverse agonists - Exploring C6 and C8 SAR using late-stage functionalizationQing Shi, Zili Xiao, Michael G Yang, et al.
Pageof 15

Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
Journal of Medicinal Chemistry|December 2, 1999
Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 2. Approaches to eliminate opioid agonist metabolites via modification of linker and 4-methoxycarbonyl-4-phenylpiperidine moietyT G Murali Dhar, D Nagarathnam, M R Marzabadi, et al.
Journal of Medicinal Chemistry|January 25, 2021
Bicyclic Ligand-Biased Agonists of S1P<sub>1</sub>: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety ProfilesJohn L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Bioorganic & Medicinal Chemistry Letters|July 2, 2019
Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonistsZhonghui Lu, James J-W Duan, Haiyun Xiao, et al.
Bioorganic & Medicinal Chemistry Letters|May 28, 2013
The discovery of BMS-457, a potent and selective CCR1 antagonistDaniel S Gardner, Joseph B Santella, John V Duncia, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Structure-based Discovery of Phenyl (3-Phenylpyrrolidin-3-yl)sulfones as Selective, Orally Active RORγt Inverse AgonistsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry|September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase InhibitorChunjian Liu, James Lin, John Hynes, et al.
Journal of Medicinal Chemistry|February 16, 2021
Tricyclic-Carbocyclic RORγt Inverse Agonists-Discovery of BMS-986313Michael G Yang, Myra Beaudoin-Bertrand, Zili Xiao, et al.
Journal of the American Chemical Society|September 15, 2022
Overcoming Limitations in Decarboxylative Arylation via Ag-Ni ElectrocatalysisMaximilian D Palkowitz, Gabriele Laudadio, Simon Kolb, et al.
Journal of Medicinal Chemistry|May 17, 2002
Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activityT G Murali Dhar, Zhongqi Shen, Junqing Guo, et al.
Bioorganic & Medicinal Chemistry Letters|September 4, 2020
Tricyclic sulfones as potent, selective and efficacious RORγt inverse agonists - Exploring C6 and C8 SAR using late-stage functionalizationQing Shi, Zili Xiao, Michael G Yang, et al.
Pageof 15